Risks

Commercial concentration in a small number of approved products can amplify payer or prescriber volatility versus broader neurology peers with more diversified revenue bases.

Rare-disease launch execution remains sensitive to reimbursement and patient-finding friction, which can slow uptake versus larger specialty peers with deeper field infrastructure.

Dependence on external manufacturing and specialty distribution channels can create supply or service disruptions, though this is partly offset by the company’s low leverage and strong liquidity versus peers.

A limited late-stage pipeline can make growth more exposed to single-asset performance than diversified biotech peers, increasing downside if adoption or label expansion underperforms expectations.

Opportunities

Approved rare-disease assets provide near-term commercial visibility, and orphan-drug economics can support faster revenue scaling versus earlier-stage biotech peers.

Strong liquidity and minimal leverage reduce financing pressure, allowing more operating flexibility than leveraged specialty pharma peers during launch and expansion periods.

If reimbursement and diagnosis rates continue improving, the company can benefit from structurally underpenetrated rare-disease markets where patient identification remains a key growth driver versus larger incumbents.

Potential label expansion or broader physician adoption could extend product lifecycles, creating upside that is more visible than in peers still dependent on clinical-stage catalysts.

Overall Score

ZVRA’s forward positioning is supported by approved rare-disease products, strong liquidity, and orphan-market growth potential, while concentration and launch-execution risks remain manageable versus peers.